New Treatment Option to Delay Type 1 Diabetes

New Treatment to Delay Type 1 Diabetes

On November 17,2022 the FDA approved a new treatment to delay the onset of type 1 Diabetes in those over 8 years of age and those who are at high risk for developing diabetes.  The drug is called teplizumab and its an anti-CD3 monoclonal antibody.  

Those that qualify need to have positive diabetes autoimmune antibodies and start to show glucose irregularities without overt symptoms.  This is referred to stage 2 diabetes.  To learn more about the other stages click on this hyperlink

The drug interferes with autoimmune destruction of the pancreatic cells that make insulin.  Insulin is needed to keep blood sugars tightly controlled.

Though this is not a cure for diabetes, its a huge milestone in the treatment/care of diabetes and it could delay the onset of type 1 diabetes by 2 years.